Telaglenastat Plus Everolimus in Advanced Renal Cell Carcinoma: A Randomized, Double-Blinded, Placebo-Controlled, Phase 2 ENTRATA Trial
Gespeichert in:
| Veröffentlicht in: | Clinical cancer research 2022-08, Vol.28 (15), p.3248-3255 |
|---|---|
| Hauptverfasser: | , , , , , , , , , , , , , , , , , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 3255 |
|---|---|
| container_issue | 15 |
| container_start_page | 3248 |
| container_title | Clinical cancer research |
| container_volume | 28 |
| creator | Lee, Chung-Han Motzer, Robert Emamekhoo, Hamid Matrana, Marc Percent, Ivor Hsieh, James J. Hussain, Arif Vaishampayan, Ulka Liu, Sandy McCune, Steven Patel, Vijay Shaheen, Montaser Bendell, Johanna Fan, Alice C. Gartrell, Benjamin A. Goodman, Oscar B. Nikolinakos, Petros G. Kalebasty, Arash Rezazadeh Zakharia, Yousef Zhang, Zhentao Parmar, Hema Akella, Lalith Orford, Keith Tannir, Nizar M. |
| description | |
| doi_str_mv | 10.1158/1078-0432.CCR-22-0061 |
| format | Article |
| fullrecord | <record><control><sourceid>pubmedcentral</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_10202043</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>pubmedcentral_primary_oai_pubmedcentral_nih_gov_10202043</sourcerecordid><originalsourceid>FETCH-pubmedcentral_primary_oai_pubmedcentral_nih_gov_102020433</originalsourceid><addsrcrecordid>eNqljN1KxDAQhYMo7vrzCEIewKz5abvFG6l1xStZSu_LtIm7kWmyNG1BX8DXNopeeC0DM2dmvnMIuRJ8JUSa3wi-zhlPlFyVZcWkZJxn4ogsRZqumZJZehz1L7MgZyG8ci4SwZNTslARyhKVL8lHbRB2aByEEUa6xSnQzWwGj7aP0jpa6BlcZzStIoS0NBgbDJ11vodbWtAKnPa9fTf6mj74qUXD7tE6_bVvETrTelZ6N8ZM_L7tIRgq6ea5roq6oPVgAS_IyQtgMJc_85zcPW7q8okdprY3ujPRD9gcBtvD8NZ4sM3fj7P7ZufnRnAZK1Hq_wmfZLlxEw</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype></control><display><type>article</type><title>Telaglenastat Plus Everolimus in Advanced Renal Cell Carcinoma: A Randomized, Double-Blinded, Placebo-Controlled, Phase 2 ENTRATA Trial</title><source>American Association for Cancer Research</source><source>EZB-FREE-00999 freely available EZB journals</source><source>Alma/SFX Local Collection</source><creator>Lee, Chung-Han ; Motzer, Robert ; Emamekhoo, Hamid ; Matrana, Marc ; Percent, Ivor ; Hsieh, James J. ; Hussain, Arif ; Vaishampayan, Ulka ; Liu, Sandy ; McCune, Steven ; Patel, Vijay ; Shaheen, Montaser ; Bendell, Johanna ; Fan, Alice C. ; Gartrell, Benjamin A. ; Goodman, Oscar B. ; Nikolinakos, Petros G. ; Kalebasty, Arash Rezazadeh ; Zakharia, Yousef ; Zhang, Zhentao ; Parmar, Hema ; Akella, Lalith ; Orford, Keith ; Tannir, Nizar M.</creator><creatorcontrib>Lee, Chung-Han ; Motzer, Robert ; Emamekhoo, Hamid ; Matrana, Marc ; Percent, Ivor ; Hsieh, James J. ; Hussain, Arif ; Vaishampayan, Ulka ; Liu, Sandy ; McCune, Steven ; Patel, Vijay ; Shaheen, Montaser ; Bendell, Johanna ; Fan, Alice C. ; Gartrell, Benjamin A. ; Goodman, Oscar B. ; Nikolinakos, Petros G. ; Kalebasty, Arash Rezazadeh ; Zakharia, Yousef ; Zhang, Zhentao ; Parmar, Hema ; Akella, Lalith ; Orford, Keith ; Tannir, Nizar M.</creatorcontrib><identifier>ISSN: 1078-0432</identifier><identifier>EISSN: 1557-3265</identifier><identifier>DOI: 10.1158/1078-0432.CCR-22-0061</identifier><identifier>PMID: 35576438</identifier><language>eng</language><ispartof>Clinical cancer research, 2022-08, Vol.28 (15), p.3248-3255</ispartof><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>230,314,780,784,885,27923,27924</link.rule.ids></links><search><creatorcontrib>Lee, Chung-Han</creatorcontrib><creatorcontrib>Motzer, Robert</creatorcontrib><creatorcontrib>Emamekhoo, Hamid</creatorcontrib><creatorcontrib>Matrana, Marc</creatorcontrib><creatorcontrib>Percent, Ivor</creatorcontrib><creatorcontrib>Hsieh, James J.</creatorcontrib><creatorcontrib>Hussain, Arif</creatorcontrib><creatorcontrib>Vaishampayan, Ulka</creatorcontrib><creatorcontrib>Liu, Sandy</creatorcontrib><creatorcontrib>McCune, Steven</creatorcontrib><creatorcontrib>Patel, Vijay</creatorcontrib><creatorcontrib>Shaheen, Montaser</creatorcontrib><creatorcontrib>Bendell, Johanna</creatorcontrib><creatorcontrib>Fan, Alice C.</creatorcontrib><creatorcontrib>Gartrell, Benjamin A.</creatorcontrib><creatorcontrib>Goodman, Oscar B.</creatorcontrib><creatorcontrib>Nikolinakos, Petros G.</creatorcontrib><creatorcontrib>Kalebasty, Arash Rezazadeh</creatorcontrib><creatorcontrib>Zakharia, Yousef</creatorcontrib><creatorcontrib>Zhang, Zhentao</creatorcontrib><creatorcontrib>Parmar, Hema</creatorcontrib><creatorcontrib>Akella, Lalith</creatorcontrib><creatorcontrib>Orford, Keith</creatorcontrib><creatorcontrib>Tannir, Nizar M.</creatorcontrib><title>Telaglenastat Plus Everolimus in Advanced Renal Cell Carcinoma: A Randomized, Double-Blinded, Placebo-Controlled, Phase 2 ENTRATA Trial</title><title>Clinical cancer research</title><issn>1078-0432</issn><issn>1557-3265</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2022</creationdate><recordtype>article</recordtype><recordid>eNqljN1KxDAQhYMo7vrzCEIewKz5abvFG6l1xStZSu_LtIm7kWmyNG1BX8DXNopeeC0DM2dmvnMIuRJ8JUSa3wi-zhlPlFyVZcWkZJxn4ogsRZqumZJZehz1L7MgZyG8ci4SwZNTslARyhKVL8lHbRB2aByEEUa6xSnQzWwGj7aP0jpa6BlcZzStIoS0NBgbDJ11vodbWtAKnPa9fTf6mj74qUXD7tE6_bVvETrTelZ6N8ZM_L7tIRgq6ea5roq6oPVgAS_IyQtgMJc_85zcPW7q8okdprY3ujPRD9gcBtvD8NZ4sM3fj7P7ZufnRnAZK1Hq_wmfZLlxEw</recordid><startdate>20220802</startdate><enddate>20220802</enddate><creator>Lee, Chung-Han</creator><creator>Motzer, Robert</creator><creator>Emamekhoo, Hamid</creator><creator>Matrana, Marc</creator><creator>Percent, Ivor</creator><creator>Hsieh, James J.</creator><creator>Hussain, Arif</creator><creator>Vaishampayan, Ulka</creator><creator>Liu, Sandy</creator><creator>McCune, Steven</creator><creator>Patel, Vijay</creator><creator>Shaheen, Montaser</creator><creator>Bendell, Johanna</creator><creator>Fan, Alice C.</creator><creator>Gartrell, Benjamin A.</creator><creator>Goodman, Oscar B.</creator><creator>Nikolinakos, Petros G.</creator><creator>Kalebasty, Arash Rezazadeh</creator><creator>Zakharia, Yousef</creator><creator>Zhang, Zhentao</creator><creator>Parmar, Hema</creator><creator>Akella, Lalith</creator><creator>Orford, Keith</creator><creator>Tannir, Nizar M.</creator><scope>5PM</scope></search><sort><creationdate>20220802</creationdate><title>Telaglenastat Plus Everolimus in Advanced Renal Cell Carcinoma: A Randomized, Double-Blinded, Placebo-Controlled, Phase 2 ENTRATA Trial</title><author>Lee, Chung-Han ; Motzer, Robert ; Emamekhoo, Hamid ; Matrana, Marc ; Percent, Ivor ; Hsieh, James J. ; Hussain, Arif ; Vaishampayan, Ulka ; Liu, Sandy ; McCune, Steven ; Patel, Vijay ; Shaheen, Montaser ; Bendell, Johanna ; Fan, Alice C. ; Gartrell, Benjamin A. ; Goodman, Oscar B. ; Nikolinakos, Petros G. ; Kalebasty, Arash Rezazadeh ; Zakharia, Yousef ; Zhang, Zhentao ; Parmar, Hema ; Akella, Lalith ; Orford, Keith ; Tannir, Nizar M.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-pubmedcentral_primary_oai_pubmedcentral_nih_gov_102020433</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2022</creationdate><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Lee, Chung-Han</creatorcontrib><creatorcontrib>Motzer, Robert</creatorcontrib><creatorcontrib>Emamekhoo, Hamid</creatorcontrib><creatorcontrib>Matrana, Marc</creatorcontrib><creatorcontrib>Percent, Ivor</creatorcontrib><creatorcontrib>Hsieh, James J.</creatorcontrib><creatorcontrib>Hussain, Arif</creatorcontrib><creatorcontrib>Vaishampayan, Ulka</creatorcontrib><creatorcontrib>Liu, Sandy</creatorcontrib><creatorcontrib>McCune, Steven</creatorcontrib><creatorcontrib>Patel, Vijay</creatorcontrib><creatorcontrib>Shaheen, Montaser</creatorcontrib><creatorcontrib>Bendell, Johanna</creatorcontrib><creatorcontrib>Fan, Alice C.</creatorcontrib><creatorcontrib>Gartrell, Benjamin A.</creatorcontrib><creatorcontrib>Goodman, Oscar B.</creatorcontrib><creatorcontrib>Nikolinakos, Petros G.</creatorcontrib><creatorcontrib>Kalebasty, Arash Rezazadeh</creatorcontrib><creatorcontrib>Zakharia, Yousef</creatorcontrib><creatorcontrib>Zhang, Zhentao</creatorcontrib><creatorcontrib>Parmar, Hema</creatorcontrib><creatorcontrib>Akella, Lalith</creatorcontrib><creatorcontrib>Orford, Keith</creatorcontrib><creatorcontrib>Tannir, Nizar M.</creatorcontrib><collection>PubMed Central (Full Participant titles)</collection><jtitle>Clinical cancer research</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Lee, Chung-Han</au><au>Motzer, Robert</au><au>Emamekhoo, Hamid</au><au>Matrana, Marc</au><au>Percent, Ivor</au><au>Hsieh, James J.</au><au>Hussain, Arif</au><au>Vaishampayan, Ulka</au><au>Liu, Sandy</au><au>McCune, Steven</au><au>Patel, Vijay</au><au>Shaheen, Montaser</au><au>Bendell, Johanna</au><au>Fan, Alice C.</au><au>Gartrell, Benjamin A.</au><au>Goodman, Oscar B.</au><au>Nikolinakos, Petros G.</au><au>Kalebasty, Arash Rezazadeh</au><au>Zakharia, Yousef</au><au>Zhang, Zhentao</au><au>Parmar, Hema</au><au>Akella, Lalith</au><au>Orford, Keith</au><au>Tannir, Nizar M.</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Telaglenastat Plus Everolimus in Advanced Renal Cell Carcinoma: A Randomized, Double-Blinded, Placebo-Controlled, Phase 2 ENTRATA Trial</atitle><jtitle>Clinical cancer research</jtitle><date>2022-08-02</date><risdate>2022</risdate><volume>28</volume><issue>15</issue><spage>3248</spage><epage>3255</epage><pages>3248-3255</pages><issn>1078-0432</issn><eissn>1557-3265</eissn><pmid>35576438</pmid><doi>10.1158/1078-0432.CCR-22-0061</doi></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 1078-0432 |
| ispartof | Clinical cancer research, 2022-08, Vol.28 (15), p.3248-3255 |
| issn | 1078-0432 1557-3265 |
| language | eng |
| recordid | cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_10202043 |
| source | American Association for Cancer Research; EZB-FREE-00999 freely available EZB journals; Alma/SFX Local Collection |
| title | Telaglenastat Plus Everolimus in Advanced Renal Cell Carcinoma: A Randomized, Double-Blinded, Placebo-Controlled, Phase 2 ENTRATA Trial |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-12T16%3A32%3A03IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-pubmedcentral&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Telaglenastat%20Plus%20Everolimus%20in%20Advanced%20Renal%20Cell%20Carcinoma:%20A%20Randomized,%20Double-Blinded,%20Placebo-Controlled,%20Phase%202%20ENTRATA%20Trial&rft.jtitle=Clinical%20cancer%20research&rft.au=Lee,%20Chung-Han&rft.date=2022-08-02&rft.volume=28&rft.issue=15&rft.spage=3248&rft.epage=3255&rft.pages=3248-3255&rft.issn=1078-0432&rft.eissn=1557-3265&rft_id=info:doi/10.1158/1078-0432.CCR-22-0061&rft_dat=%3Cpubmedcentral%3Epubmedcentral_primary_oai_pubmedcentral_nih_gov_10202043%3C/pubmedcentral%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_id=info:pmid/35576438&rfr_iscdi=true |